Helixmith Co., Ltd.
- Country
- π°π·South Korea
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 75
- Market Cap
- -
- Website
- http://helixmith.com
Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT02039401
- Locations
- πΊπΈ
Northwestern University, Chicago, Illinois, United States
Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
- Conditions
- Painful Diabetic Neuropathies
- Interventions
- Other: Control- Placebo (normal saline)
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT01475786
- Locations
- πΊπΈ
Northwestern University, Chicago, Illinois, United States
πΊπΈThe Neurosciences Institute Albany Medical College, Albany, New York, United States
πΊπΈBeth Israel Deaconess, Boston, Massachusetts, United States
Safety Study of Gene Therapy for Ischemic Heart Disease in Korea
- Conditions
- Ischemic Heart Disease
- Interventions
- Biological: VM202RY
- First Posted Date
- 2011-08-24
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT01422772
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
Efficacy and Safety Study of PG201 Tablet in Patients With Osteoarthritis
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Other: PG201Other: Placebo
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 82
- Registration Number
- NCT01122485
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
- Conditions
- Critical Limb Ischemia
- Interventions
- Biological: Low Dose VM202Biological: High Dose VM202Other: Placebo
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT01064440
- Locations
- πΊπΈ
Boston University School of Medicine, Boston, Massachusetts, United States
πΊπΈThe Methodist Hospital, Houston, Texas, United States
πΊπΈSt. Vincent Medical Group, Indianapolis, Indiana, United States
Gene Therapy for the Treatment of Chronic Stable Angina
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Helixmith Co., Ltd.
- Registration Number
- NCT01002495
- Locations
- πΊπΈ
Minneapolis Heart Institute Foundation/ Abbott Northwestern Hospital, Minneapolis, Minnesota, United States
πΊπΈNorthwestern Memorial Hospital, Chicago, Illinois, United States
Gene Therapy for Painful Diabetic Neuropathy
- Conditions
- Painful Diabetic Neuropathy
- Interventions
- Biological: VM202
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2019-10-24
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01002235
- Locations
- πΊπΈ
Diablo Clinical Research Hospital, Walnut Creek, California, United States
πΊπΈNorthwestern Memorial Hospital, Chicago, Illinois, United States
Gene Therapy for Chronic Granulomatous Disease in Korea
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 2
- Registration Number
- NCT00778882
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
Safety Study of Gene Therapy in Treating Critical Leg Ischemia
- Conditions
- Critical Limb Ischemia
- Interventions
- Biological: VM202 2 mgBiological: VM202 4 mgBiological: VM202 8 mgBiological: VM202 16 mg
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT00696124
- Locations
- πΊπΈ
Minneapolis Heart Institute Foundation/ Abbott Northwestern Hospital, Minneapolis, Minnesota, United States